Citations (44)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (11)
Ichiro Nakamura, Hiroshi Maegawa, Kazuyuki Tobe & Satoshi Uno. (2021) Real-World Evidence for Long-Term Safety and Effectiveness of Ipragliflozin in Japanese Patients with Type 2 Diabetes Mellitus: final Results of a 3-Year Post-Marketing Surveillance Study (STELLA-LONG TERM). Expert Opinion on Pharmacotherapy 22:3, pages 373-387.
Read now
Read now
Mitsuyoshi Takahara, Toshihiko Shiraiwa, Taka-aki Matsuoka, Kaoru Yamamoto, Yoshifumi Maeno, Yuka Shiraiwa, Yoko Yoshida, Naoto Katakami, Hiroaki Iijima, Hideyuki Katsumata, Kenji Arakawa, Toshio Hashimoto & Iichiro Shimomura. (2020) Investigation of the Effect of Canagliflozin on the Disposition Index, a Marker of Pancreatic Beta Cell Function, in Patients with Type 2 Diabetes. Diabetes, Metabolic Syndrome and Obesity 13, pages 4457-4468.
Read now
Read now
Hiroyuki Ito, Suzuko Matsumoto, Takuma Izutsu, Eiji Kusano, Shinya Nishio, Shinichi Antoku, Tomoko Yamasaki, Toshiko Mori, Michiko Togane, Shigenori Ando & Emiko Tsugami. (2019) Comparison of the changes in the factors associated with the renal prognosis of non-elderly and elderly subjects treated with empagliflozin- a retrospective observation study in Japanese patients with type 2 diabetes. Diabetes, Metabolic Syndrome and Obesity 12, pages 1783-1794.
Read now
Read now
Hiroshi Maegawa, Kazuyuki Tobe, Ichiro Nakamura & Satoshi Uno. (2019) Safety and effectiveness of ipragliflozin in elderly versus non-elderly Japanese type 2 diabetes mellitus patients: 12 month interim results of the STELLA-LONG TERM study. Current Medical Research and Opinion 35:11, pages 1901-1910.
Read now
Read now
André J. Scheen. (2018) The safety of empagliflozin plus metformin for the treatment of type 2 diabetes. Expert Opinion on Drug Safety 17:8, pages 837-848.
Read now
Read now
Nobuya Inagaki, Shin-ichi Harashima & Hiroaki Iijima. (2018) Canagliflozin for the treatment of type 2 diabetes: a comparison between Japanese and non-Japanese patients. Expert Opinion on Pharmacotherapy 19:8, pages 895-908.
Read now
Read now
Hiroshi Maegawa, Kazuyuki Tobe, Hiromi Tabuchi, Ichiro Nakamura & Satoshi Uno. (2018) Safety and efficacy of ipragliflozin in elderly versus non-elderly Japanese patients with type 2 diabetes mellitus: a subgroup analysis of the STELLA-LONG TERM study. Expert Opinion on Pharmacotherapy 19:4, pages 327-336.
Read now
Read now
Ichiro Nakamura, Hiroshi Maegawa, Kazuyuki Tobe, Hiromi Tabuchi & Satoshi Uno. (2018) Safety and efficacy of ipragliflozin in Japanese patients with type 2 diabetes in real-world clinical practice: interim results of the STELLA-LONG TERM post-marketing surveillance study. Expert Opinion on Pharmacotherapy 19:3, pages 189-201.
Read now
Read now
Maki Goda, Tomoko Yamakura, Kazuyo Sasaki, Takumi Tajima & Makoto Ueno. (2018) Safety and efficacy of canagliflozin in elderly patients with type 2 diabetes mellitus: a 1-year post-marketing surveillance in Japan. Current Medical Research and Opinion 34:2, pages 319-327.
Read now
Read now
Marco Tuccori, Irma Convertino, Maria Teresa Galiulo, Alessandra Marino, Alice Capogrosso-Sansone & Corrado Blandizzi. (2017) Diabetes drugs and the incidence of solid cancers: a survey of the current evidence. Expert Opinion on Drug Safety 16:10, pages 1133-1148.
Read now
Read now
Daisuke Yabe, Yoshiyuki Hamamoto, Yusuke Seino, Hitoshi Kuwata, Takeshi Kurose & Yutaka Seino. (2017) Sodium glucose co-transporter 2 inhibitor luseogliflozin in the management of type 2 diabetes: a drug safety evaluation. Expert Opinion on Drug Safety 16:10, pages 1211-1218.
Read now
Read now
Articles from other publishers (33)
Amy Kang, Brendan Smyth, Brendon L. Neuen, Hiddo J. L. Heerspink, Gian Luca Di Tanna, Hong Zhang, Clare Arnott, Carinna Hockham, Rajiv Agarwal, George Bakris, David M. Charytan, Dick de Zeeuw, Tom Greene, Adeera Levin, Carol Pollock, David C. Wheeler, Kenneth W. Mahaffey, Vlado Perkovic & Meg J. Jardine. (2023)
The sodium‐glucose cotransporter‐2
inhibitor canagliflozin does not increase risk of non‐genital skin and soft tissue infections in people with type 2 diabetes mellitus: A pooled post hoc analysis from the
CANVAS
Program and
CREDENCE
randomized double‐blind trials
. Diabetes, Obesity and Metabolism 25:8, pages 2151-2162.
Crossref
Crossref
T. L. De Backer & A. A. Mangoni. 2023. Optimizing Pharmacotherapy in Older Patients. Optimizing Pharmacotherapy in Older Patients
239
267
.
Hiroshi Takahashi, Yuka Suganuma, Takayuki Ohno & Rimei Nishimura. (2022) Trends in clinical characteristics and factors associated with initial prescription of SGLT2 inhibitors in Japanese patients with type 2 diabetes mellitus. Diabetology International 13:4, pages 606-614.
Crossref
Crossref
Maria Elena Lunati, Vincenzo Cimino, Alessandra Gandolfi, Matteo Trevisan, Laura Montefusco, Ida Pastore, Camilla Pace, Nazarena Betella, Giuseppe Favacchio, Monica Bulgheroni, Loredana Bucciarelli, Giulia Massari, Cristina Mascardi, Angela Girelli, Paola Silvia Morpurgo, Franco Folli, Livio Luzi, Marco Mirani, Basilio Pintaudi, Federico Bertuzzi, Cesare Berra & Paolo Fiorina. (2022) SGLT2-inhibitors are effective and safe in the elderly: The SOLD study. Pharmacological Research 183, pages 106396.
Crossref
Crossref
Takeshi Horii, Yoichi Oikawa, Narumi Kunisada, Akira Shimada & Koichiro Atsuda. (2021) Acute kidney injury in Japanese type 2 diabetes patients receiving sodium–glucose cotransporter 2 inhibitors: A nationwide cohort study. Journal of Diabetes Investigation 13:1, pages 42-46.
Crossref
Crossref
Su Jin Jeong, Seung Eun Lee, Dong Hyun Shin, Ie Byung Park, Hui Seung Lee & Kyoung-Ah Kim. (2021) Barriers to initiating SGLT2 inhibitors in diabetic kidney disease: a real-world study. BMC Nephrology 22:1.
Crossref
Crossref
André J. Scheen. (2021) Efficacy / safety balance of DPP-4 inhibitors versus SGLT2 inhibitors in elderly patients with type 2 diabetes. Diabetes & Metabolism 47:6, pages 101275.
Crossref
Crossref
Kohei Kaku, Takashi Kadowaki, Yutaka Seino, Taro Okamoto, Masayoshi Shirakawa, Asako Sato, Edward A. O'Neill, Samuel S. Engel & Keith D. Kaufman. (2021) Efficacy and safety of ipragliflozin in Japanese patients with type 2 diabetes and inadequate glycaemic control on sitagliptin. Diabetes, Obesity and Metabolism 23:9, pages 2099-2108.
Crossref
Crossref
Ichiro Nakamura, Hiroshi Maegawa, Kazuyuki Tobe & Satoshi Uno. (2021) Safety and Effectiveness of Ipragliflozin in Elderly Versus Non-elderly Japanese Patients with Type 2 Diabetes: Subgroup Analysis of STELLA-LONG TERM. Diabetes Therapy 12:5, pages 1359-1378.
Crossref
Crossref
Kenta Okada, Satoshi Hoshide, Mitsutoshi Kato, Hiroshi Kanegae, Shun Ishibashi & Kazuomi Kario. (2020) Safety and efficacy of empagliflozin in elderly Japanese patients with type 2 diabetes mellitus: A post hoc analysis of data from the SACRA study. The Journal of Clinical Hypertension 23:4, pages 860-869.
Crossref
Crossref
Hiroyuki Ito, Suzuko Matsumoto, Takuma Izutsu, Eiji Kusano, Jiro Kondo, Hideyuki Inoue, Shinichi Antoku, Tomoko Yamasaki, Toshiko Mori & Michiko Togane. (2021) Different renoprotective effects of luseogliflozin depend on the renal function at the baseline in patients with type 2 diabetes: A retrospective study during 12 months before and after initiation. PLOS ONE 16:3, pages e0248577.
Crossref
Crossref
Yuji Tezuka, Osamu Sekine, Akiko Hirano, Yukako Hanada, Ikuhisa Nakanishi, Misaki Ariga, Choka Azuma, Yukako Yamamoto, Jun Ito-Kobayashi, Miki Washiyama, Masanori Iwanishi, Miyuki Furuta, Masao Kanamori, Akira Shimatsu & Atsunori Kashiwagi. (2020) A Prospective, Open-Label Short-Term Pilot Study on Modification of the Skin Hydration Status During Treatment With a Sodium-Glucose Cotransporter-2 Inhibitor. Diabetes Therapy 12:1, pages 431-440.
Crossref
Crossref
Francesco Giorgino, Jiten Vora, Peter Fenici & Anna Solini. (2020) Renoprotection with SGLT2 inhibitors in type 2 diabetes over a spectrum of cardiovascular and renal risk. Cardiovascular Diabetology 19:1.
Crossref
Crossref
Ikuro Matsuba, Takehiro Kawata, Kotaro Iemitsu, Taro Asakura, Hikaru Amemiya, Masashi Ishikawa, Syogo Ito, Mizuki Kaneshiro, Akira Kanamori, Akira Kubota, Kazuaki Shinoda, Masahiko Takai, Tetsuo Takuma, Masahiro Takihata, Hiroshi Takeda, Keiji Tanaka, Yoko Matsuzawa, Hideo Machimura, Fuyuki Minagawa, Nobuaki Minami, Atsuko Mokubo, Masaaki Miyakawa, Yasuo Terauchi & Yasushi Tanaka. (2020) Effects of ipragliflozin on the development and progression of kidney disease in patients with type 2 diabetes: An analysis from a multicenter prospective intervention study. Journal of Diabetes Investigation 11:5, pages 1248-1257.
Crossref
Crossref
Francesco Giorgino, Jiten Vora, Peter Fenici & Anna Solini. (2020) Cardiovascular protection with sodium‐glucose co‐transporter‐2 inhibitors in type 2 diabetes: Does it apply to all patients?. Diabetes, Obesity and Metabolism 22:9, pages 1481-1495.
Crossref
Crossref
Chen-Ti Wang, Che-Wei Chang, Yung-Chuan Lu, Hing-Chung Lam, Shu-Ju Ku, Kuo-Bin Tseng & Yu-Hsi Kao. (2020) An atypical hyperosmolar hyperglycemic state and diabetic ketoacidosis induced by sodium–glucose cotransporter-2 inhibitors: A case report. Journal of the Formosan Medical Association 119:8, pages 1325-1328.
Crossref
Crossref
Kohei Kaku, Hiroyuki Isaka, Taishi Sakatani & Junko Toyoshima. (2020) Long‐term (52‐week) efficacy and safety of ipragliflozin add‐on therapy to insulin in Japanese patients with type 1 diabetes mellitus: An uncontrolled, open‐label extension of a phase III study. Journal of Diabetes Investigation 11:3, pages 662-671.
Crossref
Crossref
Kohei Kaku, Yusuke Naito, Masayuki Senda, Yuji Kurihara, Ryoji Gunji, Seigo Kakiuchi & Kazunori Utsunomiya. (2019) Safety and effectiveness of tofogliflozin in elderly Japanese patients with type 2 diabetes mellitus: A subanalysis of a post‐marketing study (J‐STEP/EL Study). Journal of Diabetes Investigation 11:2, pages 405-416.
Crossref
Crossref
Avivit Cahn, Ofri Mosenzon, Stephen D. Wiviott, Aliza Rozenberg, Ilan Yanuv, Erica L. Goodrich, Sabina A. Murphy, Deepak L. Bhatt, Lawrence A. Leiter, Darren K. McGuire, John P.H. WildingIngrid A.M. Gause-Nilsson, Martin Fredriksson, Peter A. Johansson, Anna Maria Langkilde, Marc S. Sabatine & Itamar Raz. (2020) Efficacy and Safety of Dapagliflozin in the Elderly: Analysis From the DECLARE–TIMI 58 Study. Diabetes Care 43:2, pages 468-475.
Crossref
Crossref
Lisa Dubrofsky, Anand Srivastava & David Z. Cherney. (2020) Sodium-Glucose Cotransporter-2 Inhibitors in Nephrology Practice: A Narrative Review. Canadian Journal of Kidney Health and Disease 7, pages 205435812093570.
Crossref
Crossref
Yuichiro Ito, James Van Schyndle, Takuya Nishimura, Toshifumi Sugitani & Tomomi Kimura. (2019) Real-World Effectiveness of Sodium Glucose Co-Transporter-2 Inhibitors in Japanese Patients with Diabetes Mellitus. Diabetes Therapy 10:6, pages 2219-2231.
Crossref
Crossref
Atsunori Kashiwagi, Marina V. Shestakova, Yuichiro Ito, Masahiro Noguchi, Wim Wilpshaar, Satoshi Yoshida & John P. H. Wilding. (2019) Safety of Ipragliflozin in Patients with Type 2 Diabetes Mellitus: Pooled Analysis of Phase II/III/IV Clinical Trials. Diabetes Therapy 10:6, pages 2201-2217.
Crossref
Crossref
Rimei Nishimura, Yuko Tanaka, Kazuki Koiwai, Kosuke Ishida, Afshin Salsali, Stefan Kaspers, Sven Kohler & Søren S. Lund. (2019) Effect of Empagliflozin on Free Fatty Acids and Ketone Bodies in Japanese Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Trial. Advances in Therapy 36:10, pages 2769-2782.
Crossref
Crossref
Fang L. Zhou, Hirotaka Watada, Yuki Tajima, Mathilde Berthelot, Dian Kang, Cyril Esnault, Yujin Shuto, Hiroshi Maegawa & Daisuke Koya. (2019) Identification of subgroups of patients with type 2 diabetes with differences in renal function preservation, comparing patients receiving sodium‐glucose co‐transporter‐2 inhibitors with those receiving dipeptidyl peptidase‐4 inhibitors, using a supervised machine‐learning algorithm (PROFILE study): A retrospective analysis of a Japanese commercial medical database. Diabetes, Obesity and Metabolism 21:8, pages 1925-1934.
Crossref
Crossref
Kohei Kaku, Hiroyuki Isaka, Junko Toyoshima & Taishi Sakatani. (2019) Clinical pharmacology study of ipragliflozin in Japanese patients with type 1 diabetes mellitus: A phase 2, randomized, placebo‐controlled trial. Diabetes, Obesity and Metabolism.
Crossref
Crossref
Yuichiro Ito, James Van Schyndle, Takuya Nishimura, Toshifumi Sugitani & Tomomi Kimura. (2019) Characteristics of Patients with Diabetes Initiating Sodium Glucose Co-transporter-2 Inhibitors (SGLT2i): Real-World Results from Three Administrative Databases in Japan. Diabetes Therapy 10:2, pages 549-562.
Crossref
Crossref
Kiyohiko Takahashi, Kyu Yong Cho, Akinobu Nakamura, Aika Miya, Arina Miyoshi, Chiho Yamamoto, Hiroshi Nomoto, Hirokatsu Niwa, Kiyohito Takahashi, Naoki Manda, Yoshio Kurihara, Shin Aoki, Yoichi M Ito, Tatsuya Atsumi & Hideaki Miyoshi. (2019) Should sulfonylurea be discontinued or maintained at the lowest dose when starting ipragliflozin? A multicenter observational study in Japanese patients with type 2 diabetes. Journal of Diabetes Investigation 10:2, pages 429-438.
Crossref
Crossref
Daisuke Yabe, Atsutaka Yasui, Linong Ji, Moon-Kyu Lee, Ronald Ching Wan Ma, Tien-Jyun Chang, Tomoo Okamura, Cordula Zeller, Stefan Kaspers, Jisoo Lee, Sven Kohler & Yutaka Seino. (2019) Safety and tolerability of empagliflozin in East Asian patients with type 2 diabetes: Pooled analysis of phase I-III clinical trials. Journal of Diabetes Investigation 10:2, pages 418-428.
Crossref
Crossref
Nobuya Inagaki, Shin-ichi Harashima, Kohei Kaku, Kazuoki Kondo, Nobuko Maruyama, Makiko Otsuka, Yutaka Kawaguchi & Hiroaki Iijima. (2018) Long-term efficacy and safety of canagliflozin in combination with insulin in Japanese patients with type 2 diabetes mellitus. Diabetes, Obesity and Metabolism 20:4, pages 812-820.
Crossref
Crossref
Takahiro Kambara, Rei Shibata, Hiroyuki Osanai, Yoshihito Nakashima, Hiroshi Asano, Kazuyoshi Sakai, Toyoaki Murohara & Masayoshi Ajioka. (2018) Use of sodium-glucose cotransporter 2 inhibitors in older patients with type 2 diabetes mellitus. Geriatrics & Gerontology International 18:1, pages 108-114.
Crossref
Crossref
Atsushi Tanaka, Michio Shimabukuro, Yosuke Okada, Isao Taguchi, Minako Yamaoka-Tojo, Hirofumi Tomiyama, Hiroki Teragawa, Seigo Sugiyama, Hisako Yoshida, Yasunori Sato, Atsushi Kawaguchi, Yumi Ikehara, Noritaka Machii, Tatsuya Maruhashi, Kosuke R. Shima, Toshinari Takamura, Yasushi Matsuzawa, Kazuo Kimura, Masashi Sakuma, Jun-ichi Oyama, Teruo Inoue, Yukihito Higashi, Shinichiro Ueda & Koichi Node. (2017) Rationale and design of a multicenter placebo-controlled double-blind randomized trial to evaluate the effect of empagliflozin on endothelial function: the EMBLEM trial. Cardiovascular Diabetology 16:1.
Crossref
Crossref
Atsunori Kashiwagi & Hiroshi Maegawa. (2017) Metabolic and hemodynamic effects of sodium-dependent glucose cotransporter 2 inhibitors on cardio-renal protection in the treatment of patients with type 2 diabetes mellitus. Journal of Diabetes Investigation 8:4, pages 416-427.
Crossref
Crossref
Maria Elena Lunati, Vincenzo Cimino, Alessandra Gandolfi, Matteo Trevisan, Laura Montefusco, Ida Pastore, Camilla Pace, Nazarena Betella, Giuseppe Favacchio, Monica Bulgheroni, Loredana Bucciarelli, Angela Girelli, Giulia Massari, Cristina Mascardi, Paola Silvia Morpurgo, Franco Folli, Livio Luzi, Marco Mirani, Basilio Pintaudi, Federico Bertuzzi, Cesare Berra & Paolo Fiorina. (2022) SGLT2-Inhibitors are Effective and Safe in the Elderly: The SOLD Study. SSRN Electronic Journal.
Crossref
Crossref